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Something is moving in European
drug research for children, but a
more focused effort concerning
all therapeutic needs is necessary
There is a well-recognised lack of suitable
paediatric therapies. This is caused by the
great difficulty in performing paediatric
clinical trials. However, a recent assessment1
evaluating and comparing ongoing and
published paediatric drug-therapy trials
found that significant therapeutic research
efforts are ongoing.
The analysis examined data from both
clinical trials in the Drug Evaluation in
Children (DEC-net) European register of
paediatric drug therapy trials2 and published
articles, and compared the results with the
WHO European Region Top 7 Burden of
Disease data for 0–14 year olds (ERBoD) to
assess adherence of research to therapeutic
needs based on documented disease impact.
The main area for which European paedia-
tric research seems to be carried out,
neoplasms, is not among the top 7 ERBoD.
The study’s data were analysed further.
Data from trials representing ongoing
research in Europe and published trials of
EU research were compared with data from
the ERBoD. Only 5% of the ongoing, and 9%
of the published, trials addressed one of the
three ERBoD areas concerning conditions
treatable with drug therapies. The most
commonly addressed, by both published
and ongoing research, was asthma: the area
of lowest burden in the Top 7 list.
Another recent analysis3 evaluated the
published trials more thoroughly and com-
pared the EU trials to the European
Medicines Agency (EMEA) priority list for
studies into off-patent paediatric medicinal
products to compare the European research
situation with paediatric drug therapy
needs. The trials addressed the infectious
and parasitic disease area most frequently
(21,4%), and only addressed four of the 25
EMEA priority conditions, the most com-
mon of which were malignant diseases (18%
of trials) and asthma (3%). This revealed a
lack of overlap between therapeutic needs
and research.
Two of the EMEA priority areas also
appear in the ERBoD: migraine and asthma.
However, while several trials (published and
ongoing) addressed asthma, only one of the
published, and none of the ongoing,
addressed migraine. A possible explanation
for such prioritisation of asthma research
may be market pressure,4 as is true for
infectious disease therapy studies.
The data evaluated show an overall lack of
response of research to documented paedia-
tric needs. Published research’s main inter-
ests involve three conditions (tumours,
asthma and infections), which are always
characterised by abundant research com-
pared with other recognised therapeutic
priorities. Thus, in Europe, children’s need
for appropriate, effective medicines often
remains neglected. Paediatric Regulation will
certainly lead to more, improved, research
but close monitoring is fundamental to
verify that such research truly reflects
children’s needs.
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How to be good at practical
procedures?
There has been increasing concerns in the
acute admission setting about the quality of
lumber punctures (LP), virtually all of which
are undertaken by doctors in training.
Traumatic (blood-stained) LP taps often
result in diagnostic uncertainty, increased
anxiety, the perception of technical incom-
petence and probably unnecessary treat-
ment and prolonged stay in hospital. An
audit of all acute LPs was recently under-
taken in our paediatric department, which
receives all GP referrals from Newcastle
upon Tyne.
Seventy-seven LPs were performed in
15 months (January 2007 to March 2008).
31% were ‘‘champagne taps’’ of zero red cells
and 21% were traumatic taps (.1000 red
cells/ml). The same standard for defining a
traumatic tap was used in a similar but
larger survey1 in which a higher rate of 35%
was reported.
We believe that in the brave new world of
competency-based training and European
Working Time Directive that novel initia-
tives will need to be introduced to master
essential procedures such as LP. Only five
LPs per month were performed in our
paediatric department, which has seven
rostered SHOs. An SHO therefore has the
opportunity to do an average of four LPs per
SHO per six-month rotation if they are
allowed to attempt each one. This is
probably insufficient to master new skills.
Possible learning opportunities currently
underutilised include regular oncology LP
lists performed under general anaesthesia.
Doctors in training can no longer rely on
‘‘being on the coal face’’ to learn all their
practical procedures.
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Pneumococcal prophylaxis for
children with sickle cell disease in
Africa
Penicillin prophylaxis and pneumococcal
vaccination are routinely used in the
United States and in Europe to prevent
invasive pneumococcal diseases (IPD) in
children with sickle cell disease (SCD).
Their usefulness in African children with
SCD has been recently challenged.1 Indeed, a
study of blood cultures in 155 SCD children
with temperatures .38uC cared for in one
medical centre in Uganda identified
Streptococcus pneumoniae in only 6% of
episodes. We agree with the authors that
large, well-constructed studies assessing the
risk of IPD in Africa are in order. However,
we would like to suggest that their relatively
small and monocentric study was perhaps
biased by the fact that large numbers of
children had succumbed to pneumococcal
sepsis before ever reaching medical care. We
believe that the available data strongly
support the suggestion that S pneumoniae
infection is a common cause of childhood
bacteraemia in Africa. In Bamako, Mali,
S pneumoniae was identified in 106 (5%) of
2049 children having a fever of 39uC or
higher, including 47 children with meningi-
tis and 44 with bacteraemic pneumonia.2
IPD caused 10% of deaths and their overall
fatality rate was 24%. Blood cultures were
positive in 1094 (6.6%) of 16 570 children
admitted to a rural district hospital in
Kenya. S pneumoniae was found in 26% of
patients 12 to 23 months old, and in 49% of
patients more than 5 years old. The pre-
dominant isolates among children who died
on the day of admission (103 deaths) was
S pneumoniae (49%).3 The same group
obtained blood cultures from 1093 children
who visited their hospital outpatient depart-
ment over a 6-month period. The incidence
of pneumococcal bacteraemia was 597 (416–
778) per 100 000 person-year of admission in
children younger than 5 years of age. Three-
quarters of episodes had a clinical focus or
required admission, or both; one in six was
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